Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care

1. Individuals ≥ 18 years of age at enrollment.

2. Self-reported Hispanic/Latino heritage.

3. Established diagnosis of T2D for at least 3 months prior to enrollment date.

4. HbA1c > 7.5% and ≤ 10.0% (58-86 mmol/mol) within the previous 6 months.

5. T2D treated with lifestyle alone or lifestyle + Metformin within the past 6 months prior to screening.

6. Ability to provide informed consent before any trial-related activities. Trial-related activities are any procedure that would not have been performed during normal management of the subject.

7. Based on the research staff's judgment, participant or participant's representative must have a good understanding, ability, and willingness to adhere to the protocol, including performance of self-monitored data collection during the wearable device portion of the study.

1. Type 1 diabetes or a history of diabetic ketoacidosis.

2. T2D treated with oral medicines other than Metformin or any injectable GLP-1 receptor agonist or insulin within the past 6 months prior to screening.

3. Life expectancy < 12 months.

4. Any active clinically significant physical or mental disease or disorder which, in the investigator's opinion, could interfere with the participation in the study.

5. History of major surgical procedures involving the stomach potentially affecting absorption of trial product (e.g., subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery).

6. Untreated pre-proliferative or proliferative retinopathy or maculopathy due to diabetes.

7. Renal impairment, defined as estimated glomerular filtration rate <30 mL/min/1.73 m2.

8. Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

9. Language barriers precluding comprehension of study activities and informed consent.

10. Participation in other research studies involving medication or device within 1 month prior to enrollment.

11. Known or suspected abuse of alcohol, narcotics, or illicit drugs.

12. Known or suspected allergy to OS, excipients, or related products.

13. Previous participation in this trial whether screened or randomized.

14. Pregnant, breast-feeding or the intention of becoming pregnant or not using adequate contraceptive measures.

15. The receipt of any investigational drug (within 12 months) prior to this trial.